Community Health Systems, Inc. (CYH) is a Franklin, Tennessee-based hospital operator that owns, leases and operates general acute care hospitals and a large network of outpatient, urgent care, imaging and ambulatory surgery sites, concentrated in smaller and mid-sized markets across roughly a dozen states. The company employs about 57,000 people and generates close to $11.5 billion in annual revenue.
In Thursday's session, the shares traded at $1.73, down $0.13, or 6.99%, from the prior closing price of $1.86. The move was decisively lower and pushed the stock to its weakest level in more than a year. No company press release, securities filing or new analyst action accompanied the drop; the decline coincided with a sharp, simultaneous selloff across listed hospital operators, pointing to sector-wide positioning rather than a single company disclosure.
The clearest explanation for Thursday's price action is sector momentum. Hospital and healthcare facilities stocks fell broadly, with HCA down 3.0%, Tenet Healthcare (THC) down 3.6% and Universal Health Services (UHS) down 5.4% at the same time. That pattern — large-cap operators off modestly, the smallest and most indebted operator off hardest — is consistent with investors reducing exposure to the group rather than reacting to one headline.
What links the group is a common set of anxieties: softer commercial elective volumes, rising medical specialist costs, growth in uninsured and self-pay admissions, and uncertainty over the durability of supplemental payment programs that support hospital economics in several states. Sector sentiment has deteriorated steadily since late October, and each leg lower has forced re-pricing across the group.
For Community Health Systems, that sector pressure is amplified by operating and financial leverage. Divestitures have shrunk reported revenue, adjusted EBITDA fell to $280 million in the third quarter from $376 million a year earlier, and the margin compressed to 10.2% from 12.2%. Because the equity sits behind more than $10 billion of debt, small changes in sector sentiment translate into outsized percentage moves in the share price.
Thursday's decline extends a slide that began with third-quarter results published Oct. 28. The company reported an adjusted loss of $0.48 per share against expectations for a loss of about $0.29, on revenue of $2.757 billion that missed consensus by roughly $50 million. Management cut full-year 2026 guidance for the second consecutive quarter, guiding to a net loss of $1.60 to $1.70 per share and adjusted EBITDA of $1.225 billion to $1.275 billion, citing elevated uninsured volumes and weakness in higher-margin commercial elective procedures.
The sell-side response has been uniformly negative. RBC Capital cut its target to $3 from $4 on Nov. 17 while keeping an Outperform rating; Wells Fargo reduced its target to $1 with an Underweight rating; Barclays moved to $2 with an Underweight rating; Truist now sits at $2.50; and Zacks Research downgraded the shares to Strong Sell while widening its full-year loss estimate. The consensus target has drifted down toward the mid-$2s, and the consensus rating sits at Hold-to-Reduce — a configuration that tends to invite further de-risking on down days rather than dip-buying.
The stock opened the session below $1.86 and never reclaimed it, closing in on levels last seen in late 2024 and undercutting Wednesday's low of $1.85 to set a new 52-week low. The shares now trade well below their 50-day moving average near $2.67 and their 200-day average near $2.97, having lost roughly 40% since mid-October. Momentum readings are deeply oversold, but oversold conditions in a highly levered equity have repeatedly failed to produce durable rallies this year, and there is little chart support beneath current levels to slow declines.
Volume has been running notably above normal. Wednesday's session traded about 2.9 million shares, nearly double the roughly 1.6 million-share average of the past 60 sessions, and activity has stayed elevated through the week. The move was fully aligned with peers and with the hospital group; it was not a company-specific dislocation, nor was it a market-wide event, since the broader indices were not down by a comparable magnitude. For a stock with a public float near 80 million shares and a market value of about $245 million, that combination — heavy volume, sector-wide selling, and a break to new lows — is the classic signature of forced and momentum-driven selling rather than fundamental re-underwriting on a single data point.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Here, the verified catalyst was weak to moderate: no new company disclosure, with the day's direction set by a sector-wide hospital retreat layered on an existing post-earnings overhang.
The price move was moderately unusual rather than extreme. At 6.99%, the decline was about 2.6 times the stock's typical daily absolute move of roughly 2.7% over the past 60 sessions, and moves of similar or larger size occurred four times in that window. Combining modest news intensity with a moderately abnormal move gives 30 out of 100.
Attention now turns to fourth-quarter results, expected in February, and to management's initial 2027 outlook — the first real test of whether the payor-mix and cost trends that drove two guidance cuts are stabilizing. Investors will watch same-store adjusted admissions, uninsured volume as a share of growth, contract labor and specialty fee trends, and free cash flow generation. Further hospital divestitures and debt reduction would be read as a positive, while any deterioration in liquidity would intensify scrutiny of the capital structure.
On the sell side, estimate revisions remain downward-skewed, and additional target cuts cannot be ruled out after a break to new lows. Sector developments matter as much as company news: hospital shares are sensitive to reimbursement policy, Medicaid supplemental payment decisions and insurer commentary on utilization. The main risks are continued volume softness in commercial orthopedics and cardiac procedures, rising bad debt, and the possibility that asset-sale proceeds are insufficient to meaningfully reduce leverage.
Tickeron's Trending AI Robots page spotlights only the strongest-performing automated strategies under current market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so results vary meaningfully across market regimes. Reviewing the curated list is a practical way to see which approaches are working right now before allocating capital to any single strategy.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CYH saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 73 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CYH turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 45 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CYH moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CYH crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for CYH entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYH advanced for three days, in 221 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CYH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.224) is normal, around the industry mean (204.532). P/E Ratio (1.176) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.498). Dividend Yield (0.452) settles around the average of (0.154) among similar stocks. P/S Ratio (0.034) is also within normal values, averaging (2.688).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. CYH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of general acute care hospitals
Industry HospitalNursingManagement